Treatment, prognostic markers, and survival in thymic neuroendocrine tumors
Open Access
- 1 October 2017
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 96 (43), e7842
- https://doi.org/10.1097/md.0000000000007842
Abstract
Neuroendocrine tumors of the thymus (NETTs) are rare but aggressive, and lead to poor overall survival. This retrospective study was designed to analyze factors that correlate with the prognosis of patients with NETTs. From 1999 to 2015, 41 ongoing patients with NETTs were enrolled in this study. The clinical data and outcome were compiled. Overall survival (OS) rate was analyzed using the Kaplan–Meier method in univariate analysis and the Cox-model was used in multivariate analysis. Of the 41 NETTs patients analyzed (31 male and 10 female), 12 were typical carcinoma, 14 were atypical carcinoma, 14 were small-cell carcinoma and, 1 was large-cell carcinoma. The median follow-up time was 29 months (range, 9.0–69.0). In total, 25 patients died of cancer-related disease by the last follow-up. The 3- and 5-year survival rates for all patients were 42.7% and 23.4%, respectively. Among the prognostic factors analyzed by multivariate analysis, low tumor grade, complete resection, and a negative chromogranin A (CgA) expression were positively correlated with survival. The surgical treatment of NETTs, CgA negative, and low grade of NETTs were associated with a statistically significant better prognosis. However, large, multicenter studies are required to fully validate these prognostic factors.Keywords
This publication has 24 references indexed in Scilit:
- The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant TumorsJournal of Thoracic Oncology, 2014
- Recurrence of thymic neuroendocrine carcinoma 24 years after total excision: A case reportOncology Letters, 2013
- Primary Neuroendocrine Tumors of the Thymus: A Multicenter Experience of 35 PatientsThe Annals of Thoracic Surgery, 2012
- Thymic Neuroendocrine TumorsAnnals of Surgery, 2010
- Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors?Journal of Clinical Oncology, 2007
- Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumoursGut, 2006
- A Clinicopathologic Study of 12 Neuroendocrine Tumors Arising in the ThymusChest, 2003
- Atypical Thymic Carcinoid and Malignant Somatostatinoma in Type I Multiple Endocrine Neoplasia SyndromeAmerican Journal of Clinical Oncology, 2003
- Prospective Study of Thymic Carcinoids in Patients with Multiple Endocrine Neoplasia Type 1Journal of Clinical Endocrinology & Metabolism, 2003
- Clinical significance of blood chromogranin A measurement in neuroendocrine tumoursAnnals of Oncology, 2001